Literature DB >> 15774543

Recurrent miscarriage and long-term thrombosis risk: a case-control study.

S Quenby1, R G Farquharson, F Dawood, A M Hughes, J Topping.   

Abstract

BACKGROUND: Recurrent miscarriage has been associated with antiphospholipid syndrome (APS) and other prothombotic conditions. We tested the hypothesis that women diagnosed as having APS as an aetiological factor for their miscarriages were at higher risk of thrombosis than those with idiopathic recurrent miscarriage.
METHODS: A retrospective case-control study was performed using validated questionnaires. A total of 141 women with recurrent miscarriage and APS alone were matched with 141 women with idiopathic recurrent miscarriage for age, number and type of pregnancy loss and number of years of follow-up. A subgroup of eight women included those who initially presented with recurrent miscarriage, thrombosis and APS.
RESULTS: The mean length of follow-up was 7.3 years and response rate 74%. The incidence of thrombosis was similar in the recurrent miscarriage and APS women (6/1000 women-years) and in the idiopathic recurrent miscarriage women (2/1000 women-years) (P = 0.18). All eight women who presented with recurrent miscarriage, APS and thrombosis reported further thrombotic events.
CONCLUSIONS: Both idiopathic and APS-associated recurrent miscarriage were associated with a similar long-term risk of thrombosis.

Entities:  

Mesh:

Year:  2005        PMID: 15774543     DOI: 10.1093/humrep/deh844

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  14 in total

Review 1.  Recurrent miscarriage, antiphospholipid antibodies and the risk of thromboembolic disease.

Authors:  M Ángeles Martínez-Zamora; Ricard Cervera; Juan Balasch
Journal:  Clin Rev Allergy Immunol       Date:  2012-12       Impact factor: 8.667

2.  VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Shannon M Bates; Ian A Greer; Saskia Middeldorp; David L Veenstra; Anne-Marie Prabulos; Per Olav Vandvik
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

3.  The haplotype M2 of the ANXA5 gene is not associated with antitrophoblast antibodies.

Authors:  Nina Rogenhofer; Laura Engels; Nadja Bogdanova; Frank Tüttelmann; Arseni Markoff; Christian J Thaler
Journal:  J Assist Reprod Genet       Date:  2013-03-27       Impact factor: 3.412

4.  Magnetic Resonance Imaging Reveals Distinct Roles for Tissue Transglutaminase and Factor XIII in Maternal Angiogenesis During Early Mouse Pregnancy.

Authors:  Gadi Cohen; Ron Hadas; Rachele Stefania; Amerigo Pagoto; Shifra Ben-Dor; Fortune Kohen; Dario Longo; Michal Elbaz; Nave Dekel; Eran Gershon; Silvio Aime; Michal Neeman
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-06-13       Impact factor: 8.311

5.  The first thrombotic event in purely obstetric antiphospholipid syndrome patients and in antiphospholipid antibody carriers: comparison of incidence and characteristics.

Authors:  Marta Tonello; Antonia Calligaro; Maria Favaro; Teresa Del Ross; Paola Veronese; Elisa Salvan; Maria Teresa Gervasi; Amelia Ruffatti
Journal:  Arch Gynecol Obstet       Date:  2020-09-03       Impact factor: 2.344

6.  Obstetric antiphospholipid syndrome and long term arterial thrombosis risk.

Authors:  Genady Drozdinsky; Eran Hadar; Anat Shmueli; Rinat Gabbay-Benziv; Shachaf Shiber
Journal:  J Thromb Thrombolysis       Date:  2017-10       Impact factor: 2.300

Review 7.  Primary thrombosis prophylaxis in antiphospholipid antibody-positive patients: where do we stand?

Authors:  Medha Barbhaiya; Doruk Erkan
Journal:  Curr Rheumatol Rep       Date:  2011-02       Impact factor: 4.592

8.  Uterine DCs are crucial for decidua formation during embryo implantation in mice.

Authors:  Vicki Plaks; Tal Birnberg; Tamara Berkutzki; Shay Sela; Adi BenYashar; Vyacheslav Kalchenko; Gil Mor; Eli Keshet; Nava Dekel; Michal Neeman; Steffen Jung
Journal:  J Clin Invest       Date:  2008-11-20       Impact factor: 14.808

9.  Effects of polyclonal IgG derived from patients with different clinical types of the antiphospholipid syndrome on monocyte signaling pathways.

Authors:  Anastasia Lambrianides; Christopher J Carroll; Silvia S Pierangeli; Charis Pericleous; Ware Branch; Jurhee Rice; David S Latchman; Paul Townsend; David A Isenberg; Anisur Rahman; Ian P Giles
Journal:  J Immunol       Date:  2010-05-17       Impact factor: 5.422

10.  Clinical characteristics and prognosis of patients with isolated thrombotic vs. obstetric antiphospholipid syndrome: a prospective cohort study.

Authors:  Hui Jiang; Chu-Han Wang; Nan Jiang; Jing Li; Chan-Yuan Wu; Qian Wang; Meng-Tao Li; Xin-Ping Tian; Jiu-Liang Zhao; Yan Zhao; Xiao-Feng Zeng
Journal:  Arthritis Res Ther       Date:  2021-05-08       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.